✦ LIBER ✦

Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor — a dose-response study in depressed patients

✍ Scribed by L. Bjerkenstedt; G. Edman; L. Flyckt; L. Hagenfeldt; G. Sedvall; F. A. Wiesel

Publisher: Springer
Year: 1985
Tongue: English
Weight: 832 KB
Volume: 87
Category: Article
ISSN: 0033-3158
DOI: 10.1007/bf00432703

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Frontal 5-HT2A receptors studied in depr

Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors

✍ J. M. Massou; C. Trichard; D. Attar-Levy; A. Feline; E. Corruble; B. Beaufils; J 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 222 KB

A comparison of side effects of selectiv

A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis

✍ Kenneth Wilson; Pat Mottram 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract ## Objective To examine the relative tolerability and side effect profile of tricyclic antidepressants and selective serotonin reuptake inhibitors in older depressed people. ## Methods A systematic literature search generated 37 randomised controlled trials of TCAs and SSRIs of which

Inhibition of 5-HT cell firing in the DR

Inhibition of 5-HT cell firing in the DRN by non-selective 5-HT reuptake inhibitors: studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms

✍ S. E. Gartside; V. Umbers; T. Sharp 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 648 KB

Early experience with CGP 4718 A (Serclo

Early experience with CGP 4718 A (Sercloremine), a new selective and reversible MAO-A and 5-HT-uptake inhibitor, in the treatment of depressive patients

✍ A. Delini-Stula; R. Fischbach; F. Gnirss; E. Bures; W. Pöldinger 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 654 KB

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal